Horizon Pharma PLC (HZNP) Stock
HZNP is no longer traded. Horizon Pharma was acquired by Amgen (AMGN) on October 6, 2023.
Prices on this page are historical; the last trade was October 5, 2023 at $116.30.
See Amgen (AMGN) stock →Horizon Pharma stock price history
HZNP final trading statistics
- Final close
- $116.30
- Final trading day
- Oct 5, 2023
- Market cap at delisting
- $26.63B
- Shares outstanding
- 229.00M
- Final 52-week range
- $60.03 – $116.38
- Avg. volume (final 3 mo.)
- 2,851,644
- All-time high (split-adj.)
- $119.91 · Oct 2021
- All-time low (split-adj.)
- $1.99 · Mar 2013
- Return since IPO
- +1171.0%
- Beta
- 1.01
- Book value / share
- $23.20
- Price / book
- 5.01
Horizon Pharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $3.63B | $521.5M | $4.87 |
| FY2021 | $3.23B | $534.5M | $4.81 |
| FY2020 | $2.20B | $389.8M | $3.82 |
| FY2019 | $1.30B | $573.0M | $1.99 |
| FY2018 | $1.21B | -$74.2M | $1.83 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Horizon Pharma PLC
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Horizon Pharma stock FAQ
What happened to Horizon Pharma stock?
Horizon Pharma was acquired by Amgen (AMGN) on October 6, 2023. HZNP stock stopped trading on the Nasdaq, with a final close of $116.30 on October 5, 2023.
Is HZNP stock still trading?
No. HZNP was delisted from the Nasdaq on October 6, 2023 and no longer trades on a U.S. exchange.
What was the last price of HZNP stock?
HZNP closed at $116.30 on its final trading day, October 5, 2023, for a market value of about $26.63B.
What were Horizon Pharma's revenue and earnings in its last full fiscal year?
Horizon Pharma reported revenue of $3.63B and net income of $521.5M in fiscal 2022, its last full year as a public company.
When did Horizon Pharma go public?
Horizon Pharma PLC stock began trading on July 28, 2011.